NewAmsterdam Pharma Co N.V.

NAMSW

Held by 8 specialist biotech funds

High Convergence

8 funds opened new positions. Next phase2 readout (Obicetrapib 10mg): Sep 2026.

BiotechnologyCEO: Michael Harvey Davidson Facp.IPO: 2021Website ↗

NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.

Catalysts

Phase 2Q2 2021Obicetrapib 5mgDyslipidemias, High Cholesterol, HypercholesterolemiaNCT04770389

Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald] (8 weeks)Enrollment:112/112Sites: 9RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2021ObicetrapibDyslipidemias, High Cholesterol, HypercholesterolemiaNCT04753606

Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] (8-weeks)Enrollment:120/120Sites: 19RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2022ObicetrapibDyslipidemias, High Cholesterol, HypercholesterolemiaNCT05266586

Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald] (12-weeks)Enrollment:119/119Sites: 16RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2023ObicetrapibDyslipidemia, Hypercholesterolemia, High CholesterolNCT05421078

Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] (8 Weeks)Enrollment:102/102Sites: 10RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2023ObicetrapibEarly Alzheimer's DiseaseNCT05161715

Primary: Mean Percent Change in Apolipoprotein A-I (ApoA-I) in Cerebrospinal Fluid (CSF) (24 weeks)Enrollment:13/13Sites: 1NA, PREVENTION

Phase 3PositiveQ2 2024ObicetrapibDyslipidemias, High Cholesterol, HypercholesterolemiaNCT05425745

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days)Enrollment:354/354Sites: 96RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2024Monotherapy obicetrapibDyslipidemias, Hypercholesterolemia, Familial HypercholesterolemiaNCT06005597

Primary: Effect of Fixed-Dose Combination (FDC) Compared to Placebo on LDL-C (84 Days)Enrollment:407/407Sites: 45RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2024PlaceboDyslipidemias, High Cholesterol, HypercholesterolemiaNCT05142722

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 84 [PUC] (84 Days)Enrollment:2,530/2,530Sites: 181RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q3 2026Obicetrapib 10mgAntioxidant AbsorptionNCT06982508

Primary: Sum of Percent Change of Antioxidant Levels within HDL (16 Weeks)Enrollment:Target 100Sites: 1RANDOMIZED, DOUBLE, BASIC_SCIENCE

Phase 2Q4 2026obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeksDyslipidemiasNCT06496243

Primary: To evaluate the effect of evolocumab in combination with obicetrapib on lipoprotein (a) (Lp[a]). (16 weeks from baseline; 8 weeks on combination therapy)Enrollment:Target 69Sites: 1NA, TREATMENT

Phase 3Q4 2026ObicetrapibAtherosclerotic Cardiovascular DiseaseNCT05202509

Primary: Major Adverse Cardiovascular Effect (MACE) (30 months after last participant randomized)Enrollment:9,541/9,541Sites: 591RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2027obicetrapib 10 mg + ezetimibe 10 mg FDC dailyLipidemia, Coronary Artery Disease, Plaque, AtheroscleroticNCT06305559

Phase 3Q1 2028obicetrapib 10 mg + ezetimibe 10 mg FDC dailyLipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (Met S)NCT07219602

Phase 2Q3 2028Obicetrapib 10 mgPreclinical Alzheimer's DiseaseNCT07794670

NewAmsterdam Pharma Co N.V.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Cash Runway

Catalysts

Activist Filings

Recent Insider Activity

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research